Gastrin-releasing peptide receptor (GRPR), overexpressed in various cancers, is a promising target for positron emission tomography (PET). This systematic review investigated the diagnostic value of GRPR-targeted PET imaging in oncology. A systematic search was conducted on major medical databases until May 23, 2024.
View Article and Find Full Text PDFObjectives: To evaluate 18F-DCFPyL-PET/MRI whole-gland-derived radiomics for detecting clinically significant (cs) prostate cancer (PCa) and predicting metastasis.
Methods: Therapy-naïve PCa patients who underwent 18F-DCFPyL PET/MRI were included. Whole-prostate-segmentation was performed.
Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0).
View Article and Find Full Text PDFPurpose: The aims of this study were to perform a comprehensive review and meta-analyses and to report pooled diagnostic results on CXCR4-targeted PET, particularly considering detection, visualization, and prognostication.
Patients And Methods: This study followed PRISMA-DTA. A systematic search was conducted on major medical literature databases up to March 1, 2024.
Rationale And Objectives: To determine the role of dynamic contrast-enhanced (DCE) MRI-radiomics in predicting the International Society of Urological Pathology Grade Group (ISUP-GG) in therapy-naïve prostate cancer (PCa) patients.
Materials And Methods: In this ethics review board-approved retrospective study on two prospective clinical trials between 2017 and 2020, 73 men with suspected/confirmed PCa were included. All participants underwent multiparametric MRI.